Cochrane · systematic review · CD006137
H1‐antihistamines for chronic spontaneous urticaria
Sharma, M, Bennett, C, Cohen, SN, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
26
current version
GRADE rated
26
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 7.7%Low 21 · 80.8%Moderate 3 · 11.5%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Cetirizine 10 to 20 mg versus placebo for chronic spontaneous urticaria
Population: patients with chronic spontaneous urticaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete suppression of urticaria Global assessment of symptom scores Cetirizine 10 to 20 mg vs placebo | RR 2.72 [1.51, 4.91] | 2 studies · 178 participants | Low Downgraded: risk of bias, imprecision |
Adverse events leading to withdrawal Cetirizine 10 to 20 mg vs placebo | RR 3 [0.68, 13.22] | 3 studies · 389 participants | Low Downgraded: risk of bias, imprecision |
Desloratadine 5 to 20 mg versus placebo for chronic spontaneous urticaria
Population: patients with chronic spontaneous urticaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete suppression of urticaria: short‐term duration of intervention (desloratadine 5 mg) Global assessment of symptom scores Desloratadine 5 to 20 mg vs placebo | no estimate extracted | 1 study · 46 participants | Low Downgraded: risk of bias, imprecision |
Complete suppression of urticaria: short‐term duration of intervention (desloratadine 10 mg) Global assessment of symptom scores Desloratadine 5 to 20 mg vs placebo | no estimate extracted | 1 study · 46 participants | Low Downgraded: risk of bias, imprecision |
Complete suppression of urticaria: short‐term duration of intervention (desloratadine 20 mg) Global assessment of symptom scores Desloratadine 5 to 20 mg vs placebo | no estimate extracted | 1 study · 46 participants | Low Downgraded: risk of bias, imprecision |
Complete suppression of urticaria: intermediate‐term duration of intervention (desloratadine 5 mg) Global assessment of symptom scores Desloratadine 5 to 20 mg vs placebo | no estimate extracted | 1 study · 80 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects leading to withdrawal: intermediate‐term duration of 5 mg of intervention Desloratadine 5 to 20 mg vs placebo | RR 1.46 [0.42, 5.1] | 3 studies · 466 participants | Low Downgraded: risk of bias, imprecision |
Levocetirizine 5 to 20 mg versus placebo for chronic spontaneous urticaria
Population: patients with chronic spontaneous urticaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete suppression of urticaria: short‐term duration of intervention (levocetirizine 5 mg) Global assessment of symptom scores Levocetirizine 5 to 20 mg vs placebo | no estimate extracted | 1 study · 49 participants | Low Downgraded: risk of bias, imprecision |
Complete suppression of urticaria: short‐term duration of intervention (levocetirizine 10 mg) Global assessment of symptom scores Levocetirizine 5 to 20 mg vs placebo | no estimate extracted | 1 study · 49 participants | Low Downgraded: risk of bias, imprecision |
Complete suppression of urticaria: short‐term duration of intervention (levocetirizine 20 mg) Global assessment of symptom scores Levocetirizine 5 to 20 mg vs placebo | no estimate extracted | 1 study · 49 participants | Low Downgraded: risk of bias, imprecision |
Complete suppression of urticaria: intermediate‐term duration of intervention (levocetirizine 5 mg) Global assessment of symptom scores Levocetirizine 5 to 20 mg vs placebo | no estimate extracted | 1 study · 100 participants | Low Downgraded: risk of bias, imprecision |
Rupatadine 10 to 20 mg versus placebo for chronic spontaneous urticaria
Population: patients with chronic spontaneous urticaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Good or excellent response Global assessment of symptom scores Rupatadine 10 to 20 mg vs placebo | RR 1.35 [1.03, 1.77] | 1 study · 245 participants | Low Downgraded: risk of bias, imprecision |
Loratadine 10 mg versus placebo for chronic spontaneous urticaria
Population: patients with chronic spontaneous urticaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Good or excellent response Global assessment of symptom scores Loratadine 10 mg vs placebo | RR 1.86 [0.91, 3.79] | 2 studies · 124 participants | Low Downgraded: risk of bias, imprecision |
Loratadine 10 mg versus cetirizine 10 mg for chronic spontaneous urticaria
Population: patients with chronic spontaneous urticaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete cessation of urticaria Global assessment of symptom scores Loratadine 10 mg vs cetirizine 10 mg | RR 1.05 [0.76, 1.43] | 2 studies · 103 participants | Low Downgraded: risk of bias, imprecision |
Loratadine 10 mg versus desloratadine 5 mg for chronic spontaneous urticaria
Population: patients with chronic spontaneous urticaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete suppression of urticaria: intermediate‐term duration of intervention Loratadine 10 mg vs desloratadine 5 mg | RR 0.91 [0.78, 1.06] | 2 studies · 369 participants | Low Downgraded: risk of bias, imprecision |
Good or excellent response: intermediate‐term duration of intervention Global assessment of symptom scores Loratadine 10 mg vs desloratadine 5 mg | RR 1.04 [0.64, 1.71] | 3 studies · 410 participants | Low Downgraded: risk of bias, imprecision |
Loratadine 10 mg versus mizolastine 10 mg for chronic spontaneous urticaria
Population: patients with chronic spontaneous urticaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete cessation of urticaria: intermediate‐term duration of intervention Global assessment of symptom scores Loratadine 10 mg vs mizolastine 10 mg | RR 0.86 [0.64, 1.16] | 3 studies · 316 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Good or excellent response: intermediate‐term duration of intervention Global assessment of symptom scores Loratadine 10 mg vs mizolastine 10 mg | RR 0.88 [0.55, 1.42] | 3 studies · 314 participants | Low Downgraded: risk of bias, imprecision |
Adverse events leading to withdrawal: intermediate‐term duration of intervention Loratadine 10 mg vs mizolastine 10 mg | RR 0.38 [0.04, 3.6] | 2 studies · 267 participants | Low Downgraded: risk of bias, imprecision |
Proportion of participants with at least 50% improvement in QoL: intermediate‐term duration of intervention Symptom score reducing index (SSRI) Loratadine 10 mg vs mizolastine 10 mg | RR 3.21 [0.32, 32.33] | 2 studies · 252 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Loratadine 10 mg versus emedastine 2 mg for chronic spontaneous urticaria
Population: patients with chronic spontaneous urticaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete cessation of urticaria: intermediate‐term duration of intervention Global assessment of symptom scores Loratadine 10 mg vs emedastine 2 mg | RR 1.04 [0.78, 1.39] | 1 study · 161 participants | Moderate Downgraded: imprecision |
Good or excellent response: intermediate‐term duration of intervention Global assessment of symptom scores Loratadine 10 mg vs emedastine 2 mg | RR 1.09 [0.96, 1.24] | 1 study · 160 participants | Moderate Downgraded: imprecision |
Adverse events leading to withdrawal: intermediate‐term duration of intervention Loratadine 10 mg vs emedastine 2 mg | RR 1.09 [0.07, 17.14] | 1 study · 161 participants | Moderate Downgraded: imprecision |
Loratadine 10 mg versus hydroxyzine 25 mg for chronic spontaneous urticaria
Population: patients with chronic spontaneous urticaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete suppression of urticaria: short‐term duration of intervention Global assessment of symptom scores Loratadine 10 mg vs hydroxyzine 25 mg | RR 1 [0.32, 3.1] | 1 study · 12 participants | Low Downgraded: risk of bias, imprecision |
Cetirizine 10 mg versus hydroxyzine 25 mg for chronic spontaneous urticaria
Population: patients with chronic spontaneous urticaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Adverse events leading to withdrawal Cetirizine 10 mg vs hydroxyzine 25 mg | RR 0.78 [0.25, 2.45] | 2 studies · 261 participants | Low Downgraded: risk of bias, imprecision |
Hydroxyzine 25 mg versus placebo for chronic spontaneous urticaria
Population: patients with chronic spontaneous urticaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Adverse events leading to withdrawal: intermediate‐term duration of intervention Hydroxyzine 25 mg vs placebo | RR 3.64 [0.77, 17.23] | 2 studies · 270 participants | Low Downgraded: risk of bias, imprecision |